Tromsø, Norway, 7 February 2019 - Biotec Pharmacon's (OSE: Biotec) subsidiary ArcticZymes adds its first ligase enzyme, T4 DNA ligase, to its portfolio. T4 DNA ligase, the most widely used enzyme in the ligase family, works by joining DNA fragments together. It is used in the development of kits and products serving the In Vitro Diagnostic (IVD) and molecular research market segments.
This launch represents the Company’s first non-novel enzyme in its expanding portfolio and fulfils customer requests for such enzymes. The high-quality and commercial grade ligase is produced under the strict ISO 13485 guidelines. It fits synergistically in the Company’s portfolio and can be used by customers either in combination with their own enzymes or alongside ArcticZymes novel enzymes.
ArcticZymes has several other ligase products in development. Numerous prototypes of novel ligases are currently with leading commercial customers for early access evaluations. Customer feedback from these evaluations will then steer the Company’s plans to commercialise further ligases in 2019.
Jethro Holter, Managing Director ArcticZymes said:
“The launch of the T4 DNA ligase fits with our strategy to expand our current portfolio beyond novel enzyme products. Our goal is to continue to leverage our experience to grow a synergistic portfolio through organic and non-organic growth initiatives.
“As a trusted component supplier to the industry we are transitioning the business towards becoming the leading one-stop shop for molecular biology enzymes.”
About Biotec Pharmacon ASA
Biotec Pharmacon is a Norwegian life sciences company focused on specialized, novel enzyme and immunomodulating beta-glucan technology.
The Biotec Pharmacon Group is creating value from innovation in life science markets via its subsidiaries, ArcticZymes and Biotec BetaGlucans. Its technologies capitalize on more than three decades of world-class research at the Arctic University of Tromsoe to offer niche and high tech products in several biotech segments.
ArcticZymes develops, manufactures and commercialises novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.
Biotec BetaGlucans develops, produces and markets immunomodulating beta-glucans addressing high unmet healthcare needs, such as chronic wound healing and as an adjuvant in vaccines against certain types of cancer relapse.
Listed on the Oslo Stock Exchange since 2005 under the [Biotec] ticker, Biotec Pharmacon is headquartered in Tromsoe, Norway, in the SIVA Innovation Centre.
Biotec Pharmacon’s unique IP and capabilities are protected via a large portfolio of patents around both enzyme and beta-glucan products.
For more information, please visit the website: www.biotec.no.
ArcticZymes develops, produces and markets novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.
The Company focuses on novel and high-quality enzyme technologies in growth markets where rapid technological developments are creating a strong demand for new and improved enzymes.
Some of its enzymes’ unique features include heat lability and activity in challenging environments as well as customised, engineered novel features which can be integrated to power the technologies of commercial partners.
All ArcticZymes products are ISO certified.
For more information, please visit: www.arcticzymes.com.
Issued for and on behalf of Biotec Pharmacon by Instinctif Partners.
For more information please contact: Biotecpharmacon@instinctif.com.
Sue CharlesManaging Partner